Webinar Instructions

Welcome!

• Every participant is muted upon entry.
• To ask public questions, use the **Q&A** bar (right side of your screen). We encourage you to save these for the end.
• You can also use the “chat” service to send private messages to the host.
• After the webinar, additional questions can be emailed to: *KidsFirst@od.nih.gov*.

*This webinar will be recorded.*
*We will start at 12pm (ET)*
Pre-Application Webinar for

PAR-21-040, Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)

December 9, 2020
12:00 pm EST
Vision

Alleviate suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community.
Kids First Major Initiatives

1. Identify & sequence cohorts of children with **childhood cancer and/or structural birth defects**.
2. Build the **Gabriella Miller Kids First Data Resource** to empower discovery
The Kids First Dataset is Growing!

40 projects | 40,000 genomes | 16,000 cases | 16 released datasets

- Disorders of Sex Development
- Congenital Diaphragmatic Hernia
- Ewing Sarcoma
- Structural Heart & Other Defects
- Syndromic Cranial Dysinnervation Disorders
- Cancer Susceptibility
- Adolescent Idiopathic Scoliosis
- Neuroblastomas
- Enchondromatoses
- Orofacial Clefts in Caucasian, Latin American, Asian & African, Filipino populations
- Osteosarcoma
- Familial Leukemia
- Kidney and Urinary Tract Defects
- Craniofacial Microsomia
- Microtia in Hispanic Populations
- Hemangiomas, Vascular Anomalies & Overgrowth
- Intersection of childhood cancer & birth defects
- Esophageal Atresia and Tracheoesophageal Fistulas
- Nonsyndromic Craniosynostosis
- Bladder Exstrophy
- Hearing Loss
- Cornelia de Lange Syndrome
- Intracranial & Extracranial Germ Cell Tumors
- Fetal Alcohol Spectrum Disorders
- Myeloid Malignancies + overlap with Down syndrome
- Congenital Heart Defects & Acute Lymphoblastic Leukemia in Children with Down Syndrome
- Structural Brain Defects
- Structural Defects of the Neural Tube (Spina Bifida: Myelomeningocele)
- CHARGE Syndrome
- Laterality Birth Defects
- T-cell Acute Lymphoblastic Leukemia
- Pediatric Rhabdomyosarcoma
- Valvar Pulmonary Stenosis
The Kids First Data Resource for Collaborative Discovery

**Data Resource Portal**
Entry point. Query, search, discover, build & visualize synthetic cohorts

**Cavatica**
Pull data from multiple sources into one workspace. Use notebooks, bring-your-own or use available workflows.

**Knowledge Base Integrations (PedcBioPortal)**
Integrations with existing curated/published data visualizations

**Data Services**
Model clinical data in FHIR-based data services for semantic interoperability and coordination

**Framework Services**
Index and point to files in the cloud (for approved users)
PAR-21-040

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
2021 X01: 7\textsuperscript{th} Cycle

**Purpose**: To support the whole genome sequencing of cohort projects that seek to elucidate the genetic etiology of childhood cancer & structural birth defects

- WGS, WES, RNAseq for *tumors* or *affected tissue*, when justified

[https://commonfund.nih.gov/kidsfirst/x01projects](https://commonfund.nih.gov/kidsfirst/x01projects)
X01 mechanism

• Not an “award”; Recipients are selected for the opportunity to have their cohort sequenced by Kids First sequencing centers and data shared through the Kids First Data Resource

• No Notice of Award; Kids First can provide a letter acknowledging and explaining that your project was selected for the X01 program

• Not listed in the NIH RePORTER
  – Abstracts and X01 information listed on Kids First website: https://commonfund.nih.gov/kidsfirst/fundedresearch

• No funds, but can apply for other grants (e.g. Kids First R03) to support analysis of X01 project.
X01 Selection Considerations

Following **scientific peer review**, Kids First program officers evaluate projects based on the following factors, and selections are finalized by Kids First Working Group Co-Chairs.

- Scientific and technical merit (determined by scientific peer review).
- Value of incorporating the dataset into the Data Resource to empower research among the pediatric research community.
- Balance of childhood cancers and birth defects; conditions not previously sequenced will be prioritized.
- Broad data sharing and use
- Informative study design and sufficient clinical and phenotypic data.
- Availability of samples in timely manner.
- Sample quality in terms of suitability for whole genome sequencing (as well as exome and RNASeq if applicable).
Sequencing & Variant Calling

Sequencing Centers perform sequencing & variant calling
Generate aligned reads (CRAM/BAM) & variant call files

• **Germline/Normal**: WGS at 30X coverage (NovaSeq)
• **Tumor or Affected tissue** (when available/justified):
  – HudsonAlpha St Jude: 30X WGS + 100X WES + 100X RNASeq
  – Broad: 60X WGS, RNASeq

➤ You may propose other approaches (e.g., higher coverage or complementary exome sequencing).
➤ Project design will be finalized in discussions with NIH
➤ Collaborate with sequencing centers on custom analysis or validation of variants for a subset of cases
The Kids First DRC is charged with:

- re-processing and “harmonizing” data generated by the sequencing centers to facilitate analyses across all Kids First datasets
- providing a central portal where these data and analysis tools will be readily accessible to the research community

X01 investigators are encouraged to utilize and work collaboratively with the Kids First Data Resource Center to pursue specific analyses. Visit: kidsfirstdrc.org
CAVATICA Cloud Credits for X01s

- CAVATICA is a cloud-based analysis platform where researchers run multiple workflows
- X01s receive $1000 in cloud credits upon delivery of sequence data
- Intended to kick off your analysis & become familiar with the platform
- X01 investigators can request additional credits
dbGaP & the DRC

Data is made accessible through dbGaP & the Kids First Data Resource

• While the Data Resource is the NIH designated repository for Kids First data, all Kids First projects are registered, authenticated, and approved through dbGaP

• All dbGaP Data Access Requests (DARs) will be processed by the Kids First Data Access Committee run by the NCI Office of Data Sharing
Goals & Expectations

**Overall Goal**
Identify a diversity of childhood cancer and structural birth defects cohorts to generate high quality and broadly shareable and usable genomic datasets that will be valuable to the pediatric research community.
Sequencing

Goal: Generate high quality whole genome sequence and variant data from childhood cancer and structural birth defects cohorts.

WGS, whole exome sequencing (WES), and RNA sequencing may be available for tumor or affected tissue, when justified.

Expectations:

• DNA extractions must be of sufficient quality and concentration for WGS (and/or WES).
• RNA extractions (for tumor/affected tissue) must be of sufficient quality and concentration for RNASEq.
• Extractions will be ready to ship shortly after selection
Volume/Concentration Recommendations

Can be found on our FAQ page:  https://commonfund.nih.gov/kidsfirst/FAQ

<table>
<thead>
<tr>
<th>Amount of DNA/RNA and coverage</th>
<th>Amount DNA or RNA required/recommended</th>
<th>Concentration</th>
<th>Coverage</th>
<th>Additional info.</th>
</tr>
</thead>
<tbody>
<tr>
<td>WGS</td>
<td>~2 ug DNA</td>
<td>20-50 ng/ul</td>
<td>30X</td>
<td>paired end reads</td>
</tr>
<tr>
<td>WES</td>
<td>275 ng DNA (minimum); 1 ug recommended</td>
<td>20 ng/ul</td>
<td>100X, greater than 80% coding exons covered at 20X</td>
<td>paired end reads</td>
</tr>
<tr>
<td>RNA-Seq</td>
<td>750 ng total RNA (minimum); 1 ug recommended</td>
<td>20 ng/ul</td>
<td>100X, greater than 40% coding exons covered at 20X</td>
<td>paired end reads</td>
</tr>
</tbody>
</table>
Sequencing: “Difficult” Samples

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formalin-fixed paraffin-embedded (FFPE) tissue*</td>
<td>Sequencing Center can help with extractions (may result in higher costs)</td>
</tr>
<tr>
<td>Saliva-derived DNA*</td>
<td>Bacterial contamination may require additional coverage (higher costs)</td>
</tr>
<tr>
<td>Cell-line derived DNA</td>
<td>Will not be accepted</td>
</tr>
<tr>
<td>DNA/RNA from de-calcified tumors</td>
<td>Will not be accepted</td>
</tr>
</tbody>
</table>

*Sequencing Centers are experienced with “difficult” samples. For additional information, contact:
Data Sharing

Goals:
1. Make data generated by Kids First as accessible and usable as possible to the research community.
2. Enable researchers to easily combine/compare datasets for cross-disease analyses.

Expectations:
• Individual-level sequence and relevant phenotypic data are approved for deposition in a NIH-approved repository (e.g. dbGaP)
• Samples that are consented in a way that allows broad access and use, including combining and cross-analyzing datasets (General Research Use, Health/Medical/Biomedical), will be prioritized

See below and visit Kids First Genomic Data Sharing FAQs for more information
X01 Data Access & Six Month Pre-Release Period

- X01 investigators have six (6) months of proprietary access to the dataset before it is made available to the public.
- Pre-release period starts when the X01 team has access to all individual level sequence data (BAM/CRAM, VCFs).

Access Sequence Data!

### Pre-release Analyses

- **0-6 months**
  - X01 PIs & Collaborators
    - (including Kids First Sequencing Centers & DRC)

- **6+ months**
  - Pediatric Research Community
    - (request access via dbGaP)

Public Release
Analysis Plans

**Goal:** Have investigators demonstrate that the proposed project has an adequate research design for genetic discovery, and that the X01 applicants are prepared to perform these analyses

**Expectations:**
- While Kids First recognizes that analytical power will increase when the data from each individual study is incorporated with other data that will be part of the Data Resource, it is important to demonstrate that the data will be useable on its own.
- Consider partnering with other research teams with relevant expertise to develop the analysis plan.
Study Design

**Goal**: Study design, sample size, and family structures are sufficient to lead to genetic discovery

**Expectations**:

- Large sample sizes preferred
  - Consider collaborating with other investigators to pool samples together
- Non-trio family designs: describe the number of probands and affected/unaffected family members proposed for sequencing
Clinical/Phenotypic Data

**Goal:** Well-phenotyped data empowers analyses and informs how pathways/conditions overlap. The DRC will leverage existing community standards to harmonize clinical/phenotypic data which facilitates searching, analysis, and interoperability with other data efforts.

**Expectations:**
- Basic data elements are expected and deep phenotyping is preferred.
- Describe what clinical/phenotypic information is available and how these data will:
  1) support your proposed analysis
  2) contribute to the DRC to empower collaborative research
Program Balance

**Goal**: Broaden the diversity of both childhood cancer and structural birth defects datasets that are represented in the Data Resource

**Expectation**: Priority may be given to cohorts representing conditions not previously sequenced by Kids First (if many applications score well and meet other criteria)
Long-read sequencing

• Long-read sequencing technologies may be proposed to uncover genetic structural variation underlying childhood cancers and structural birth defects. Kids First Pilot.
  – Pacific Biosciences (HiFi/CCS, CLR)
  – Oxford Nanopore Technology

• Must provide strong evidence that long-read sequencing will further discovery efforts
  – Pre-liminary analyses on standard/Illumina and/or literature; public sharing of associated short-read data
  – Trios or tumor-normal matches preferred

• Stricter sample requirements
**Sample Requirements for Long Read Sequencing**

### PacBio Sequel II Sequencing

- **Volume of DNA**
  - Minimum: 5 μg of HMW DNA
  - Ideal: >7 μg*

- **Concentration**
  - 16ng/μL minimum concentration

- **Configurations available**
  - Circular Consensus Sequencing (CCS), 10kb reads
    - Provides ~6x unique read coverage
  - Linear Continuous Long Read (CLR), >25kb
    - Comparable to ~15-20x coverage of whole human genome.

### ONT PromethION Sequencing

- **Volume of DNA**
  - Minimum: 3 μg of HMW DNA
  - Ideal: >5 μg*

- **Concentration**
  - 15 ng/μL minimum concentration

- **Configurations available**
  - No fragmentation steps
  - Length of DNA = Length of the Read
  - Run time - ~3 days for 48 samples.

*To allow a buffer for quantification differences
Other Attachments

1) Institutional Certification (or provisional certification with data use limitations designations)
2) Sample Information
3) Clinical/Phenotypic Data
4) Family Structure (Optional)
Institutional Certification: Steps

1) Download the current NIH Institutional (or Provisional) Certification template: https://osp.od.nih.gov/scientific-sharing/institutional-certifications/
   *template was updated on November 1, 2018*

2) Fill out the first page, include all sites contributing samples for sequencing.

3) Provide the Institutional Certification to the IRB (or equivalent) along with the participant consent forms for each site and any other pertinent information.

4) The IRB reviews the consent form(s) to determine the data use limitations (DULs) and/or DUL modifiers for each consent form.

   - “General Research Use” with no modifiers is expected for individual-level data, unless specific uses are clearly prohibited in the participant consent
   - “Unrestricted” access is expected for genomic summary results unless the IRB provides a justification for designating the dataset as “sensitive”

5) After IRB review, the Institutional Certification is signed by the appropriate officials and submitted to NIH.

Download a letter that explains these steps
Institutional Certification: Page 1

Date: 12/03/2018
Name of GPA: Jaime Guidry Auvil
Genomic Program Administrator
NIH, HHS
9000 Rockville Pike
Bettscda, MD 20892-7395

Re: Institutional Certification of Submission of the Dataset from [NAME OF INSTITUTION] to Accompany [ORIGINAL STUDY NAME] for [PROJECT TITLE FOR DATA TO BE SUBMITTED] to an NIH-designated data repository.

Dear Jaime Guidry Auvil,

The submission of data to the NIH-designated data repository is being made with institutional approval from ____________, along with appropriate institutional approvals from collaborating sites, as listed here:

[If applicable enter collaborating site names here and click 'Add to list']

LIST OF COLLABORATING SITES

[Add list]

The ______________________ hereby assures that submission of data from the study entitled ______________________ to an NIH-designated data repository meets the following expectations, as defined in the NIH Genomic Data Sharing Policy:

- The data submission is consistent, as appropriate, with applicable national, tribal, and state laws and regulations as well as relevant institutional policies.
- Any limitations on the research use of the data, as expressed in the informed consent documents, are delineated in the table on page 3.
- The identities of research participants will not be disclosed to NIH-designated data repositories.
- An Institutional Review Board (IRB), and/or Privacy Board, and/or equivalent body, as applicable, has reviewed the investigator's proposal for data submission and assures that:
  - The protocol for the collection of genomic and phenotypic data is consistent with 45 CFR Part 46;²
  - Data submission and subsequent data sharing for research purposes are consistent with the informed consent of study participants from whom the data were obtained;
  - Consideration was given to risks to individual participants and their families associated with data submitted to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results;
  - To the extent relevant and possible, consideration was given to risks to groups or populations associated with submitting data to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results;
  - The investigator's plan for de-identifying datasets is consistent with the standards outlined in the NIH Genomic Data Sharing Policy (See section IV.C.1).

*Certification must be provided for all sites contributing samples. If more than one site is contributing samples, the primary site may submit one Institutional Certification indicating that they are providing certification on behalf of all contributing sites. Alternatively, each site providing samples may provide its own Institutional Certification.
The individual-level data are to be made available through (check one):

- controlled-access
- unrestricted access

If unrestricted access is marked, the data use limitations table on the following page(s) does not need to be completed.

NIH provides genomic summary results (GSR) from most studies submitted to NIH-designated data repositories through unrestricted access. However, data from data sets considered to have particular ‘sensitivities’ related to individual privacy or potential for group harm (e.g., those with populations from isolated geographic regions, or with rare or potentially stigmatizing traits) may be designated as “sensitive” by

In such cases, “controlled-access” should be checked below and a brief explanation for the sensitive designation should be provided. GSR from any such data sets will only be available through controlled-access.

The genomic summary results (GSR) from this study are only to be made available through controlled-access.

Explanation if controlled-access was selected for GSR.

Keep unchecked for “unrestricted” access to genomic summary results unless the IRB provides a justification for designating the dataset as “sensitive”
Institutional Certification: Page 3

NIH expects the submitting institution(s) to select one of the three standard Data Use Limitations (DULs) for appropriate secondary use, or, if necessary, create a customized DUL. DULs are developed based on the original informed consent of the participant(s).

### Data Use Limitations

<table>
<thead>
<tr>
<th>General Research Use</th>
<th>GRU</th>
<th>Use of the data is limited only by the terms of the Data Use Certification: these data will be added to the dbGaP Collection.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health/Medical/Biomedical</td>
<td>HMB</td>
<td>Use of the data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.</td>
</tr>
<tr>
<td>Disease-specific [list disease]</td>
<td>DS</td>
<td>Use of the data must be related to the specified disease.</td>
</tr>
<tr>
<td>Other</td>
<td>[ENTER CUSTOMIZED TEXT, IF APPLICABLE]</td>
<td></td>
</tr>
</tbody>
</table>

Additional modifiers to the standard DULs (e.g., Not-for-profit Use Only) based on the informed consent from the participants or in special knowledge.

### Data Use Limitation Modifiers (Optional)

| IRB Approval Required | IRB | Requestor must provide documentation of local IRB approval. |
| Publication Required | PUB | Requestor agrees to make results of studies using the data available to the larger scientific community. |
| Collaboration Required | COL | Requestor must provide a letter of collaboration with the primary study investigator(s). |
| Not-for-profit Use Only | NPU | Use of the data is limited to not-for-profit organizations. |
| Methods | MDS | Use of the data includes methods development research (e.g., development and testing of software or algorithms). |
| Genetic Studies Only | GSO | Use of the data is limited to genetic studies only. |

"General Research Use" with no modifiers is expected for individual-level data, unless specific uses are clearly prohibited.

Using the tables above, please indicate in the table below the consent group(s) for each collaborating study site. Use one row per consent group.

<table>
<thead>
<tr>
<th>Collaborating Site Name</th>
<th>Data Use Limitation</th>
<th>Data Use Limitation Modifiers (optional)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eg: Cold Cohort Study</td>
<td></td>
<td>IRB ☐ PUB ☐ COL ☐ NPU ☐ MDS ☐ GSO ☐</td>
</tr>
</tbody>
</table>
The following data use limitations and modifiers limit broad data access and impede the ability of the Kids First program to accomplish its goals

- **Disease Specific Consent Group:** When data use is restricted to a specific disease area, the data cannot be combined with a dataset with a different disease specific data use limitation. Combining and cross-analyzing datasets are a primary goal of Kids First and therefore datasets that are consented for General Research Use and/or Health/Medical/Biomedical purposes will be prioritized over datasets restricted to Disease Specific use.

- **IRB modifier:** With this box checked, the Requester must provide documentation of their local IRB’s approval for the proposed research. We find that it is rare for consent language to include such a requirement and that this modifier is often included in error. As a reminder, every requester and their institution must agree to the terms of the Data Use Certification (DUC), which verifies that the requesting PI is accredited within the institution, the institution is aware of the project for which the PI is proposing to use the data, and that the Institution has all appropriate security measures in place to manage and maintain the controlled-access dataset(s) being retrieved. For a sample DUC, see: [https://osp.od.nih.gov/wp-content/uploads/Model_DUC.pdf](https://osp.od.nih.gov/wp-content/uploads/Model_DUC.pdf)

- **COL modifier:** This box is checked when the consent form states that collaboration with the original/submitting investigator is required in order to use the dataset; therefore, the Requestor must provide a collaboration agreement document in order to be approved for access the dataset. This can limit the number of end-users who are able to use the dataset.

*For more detail on DUL definitions:*
Genomic Data Sharing Contacts

Jaime M. Guidry Auvil, Ph.D.
Genomic Program Administrator (GPA)
Director, NCI Office of Data Sharing
NCIOfficeofDataSharing@mail.nih.gov

Vivian Ota Wang, Ph.D.
Kids First Data Access Committee (DAC) Chair
Deputy Director, NCI Office of Data Sharing
KidsFirstDAC@nih.gov

General NIH Genomic Data Sharing questions: GDS@mail.nih.gov
Other Attachments

1) Institutional Certification (or provisional certification with description of data use limitations)
2) Sample Information
3) Clinical/Phenotypic Data
4) Family Structure (Optional)

[fillable tables](https://commonfund.nih.gov/kidsfirst/FAQ)
### Provisional Certification: Data Sharing and Data Use Limitations

If you provided a Provisional Institutional Certification, because you are unable to provide a full Institutional Certification, please describe the anticipated data use limitations based on the language of the consent form(s) signed by the participants in the proposed cohort. For a list of standard DULs and modifiers, please review the Institutional Certification template: [https://osp.od.nih.gov/scientific-sharing/institutional-certifications](https://osp.od.nih.gov/scientific-sharing/institutional-certifications) or [https://osp.od.nih.gov/wp-content/uploads/standard_data_use_limitations.pdf](https://osp.od.nih.gov/wp-content/uploads/standard_data_use_limitations.pdf).

<table>
<thead>
<tr>
<th>Site</th>
<th>Data Use Limitation (GRU, HMB, DS)</th>
<th>Data Use Limitation Modifiers (IRB, PUB, COL, NPU, MDS, GSO)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
# Other Attachments: Fillable Table

## Sample Information

<table>
<thead>
<tr>
<th>DNA (and RNA) tissue of origin</th>
<th>Number of Samples</th>
<th>Extraction Method</th>
<th>Concentration</th>
<th>Quality (Metric used: [edit here to specify])</th>
<th>Method of Quantitation</th>
<th>Number of Samples Ready to Ship by August 2019</th>
<th>Number of Samples Ready to Ship by January 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saliva or Buccal swab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[other tissue, edit here to describe]. Note: cell lines will not be accepted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tumors or Affected Somatic Tissue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA – Frozen Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA – Frozen Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA – Embedded Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA – Embedded Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For tumor specimens or affected tissue samples, please also describe the fixation methods and the pathology review to which the specimens were subjected, separate from the table. For tumors, describe the percentage of tumor cells within the specimen used for DNA and/or RNA isolation and % necrosis.*
**Other Attachments: Fillable Table**

**Clinical/Phenotypic Data & Demographics**

**Available Phenotype or Clinical Information (for #3 Clinical, Phenotypic, and Demographic Data).** Please edit or add to the table below to indicate what phenotype information is available for the case/proband, parents, and/or other family members. The information you list is intended to be shared through the Kids First Data Resource.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Case/Proband/Affected</th>
<th>Unaffected family members/parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>o Age at enrollment or age at diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Other age information (age at specimen collection, age at death etc....)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Hispanic ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o List any other demographic information:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical information (e.g., diagnoses, type of birth defect, primary tumor type, vital status, age at last know vital status, treatment information).</th>
<th>Case/Proband/Affected</th>
<th>Unaffected family members/parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>List the variables:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Are electronic health records available?                                                                                         |                       |                                   |

<table>
<thead>
<tr>
<th>Other phenotypic information (e.g., other phenotypic measurements that may be related to the primary outcome)</th>
<th>Case/Proband/Affected</th>
<th>Unaffected family members/parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>List the variables</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family medical history (e.g., family history of birth defects, family history of cancer)</th>
<th>Case/Proband/Affected</th>
<th>Unaffected family members/parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>List the variables:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Biospecimen & Phenotypic Data Elements

<table>
<thead>
<tr>
<th>Field</th>
<th>Description</th>
<th>Cohort type</th>
<th>Requirements</th>
<th>Data Type</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aliquot ID</strong></td>
<td>Biomatirial aliquot ID sent to the sequencing center. Some participants or samples may have multiple aliquots and as such should have a separate entry per aliquot sent to the sequencing center. The Aliquot ID could be identical to a Participant ID in the case where there is only one aliquot per individual being sent to the sequencing center.</td>
<td>All</td>
<td>Required</td>
<td>Free text</td>
<td>A216735-01a, 1249521A_1, 147192-b, 729-125-P1, 800-555_1</td>
</tr>
<tr>
<td><strong>Sample ID</strong></td>
<td>If multiple aliquots have been sent from the same sample (e.g., for WGS and RNA-Seq characterization) a sample ID that links them together.</td>
<td>All</td>
<td>Optional</td>
<td>Free Text</td>
<td>S003-125, 124952, 147, 729-125-P1, 800-555</td>
</tr>
<tr>
<td><strong>Participant ID</strong></td>
<td>Deidentified unique ID for a participant.</td>
<td>All</td>
<td>Required</td>
<td>Free text</td>
<td>A215735-01, 1249521A, 147192-b, 729-125-P1, 800-555</td>
</tr>
<tr>
<td><strong>Family ID</strong></td>
<td>Family Group ID</td>
<td>All</td>
<td>Required</td>
<td>Free text</td>
<td>167, 21717, 729-125, 800-556</td>
</tr>
<tr>
<td><strong>Consent Group</strong></td>
<td>Indicate which data use limitation, as indicated on the provided Institutional Certification, is associated with each participant.</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>General Research Use (GRU), Research Use with-not-For Use only (GRU-NU)</td>
</tr>
<tr>
<td><strong>Affected Status</strong></td>
<td>If the participant is considered affected as part of the study.</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>TRUE, TRUE, FALSE, FALSE, Not Applicable</td>
</tr>
<tr>
<td><strong>Sample Composition</strong></td>
<td>Saliva, Blood, Solid Tissue, Derived Cell Lines</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>Blood, Saliva, solid tissue, buccal cells</td>
</tr>
<tr>
<td><strong>Sample Anatomical Location</strong></td>
<td>If blood, draw location is known or other method of blood acquisition. In the case of tissue biopsy samples, note the location of the biopsy. If possible, please use the Uberon ontology.</td>
<td>All</td>
<td>Optional</td>
<td>Selection</td>
<td>Not Available, Not Available, Mouth, R adrenal gland, Cheek and Mouth</td>
</tr>
<tr>
<td><strong>Sample Method of Procurement</strong></td>
<td>biopsy, tumor resection, autopsy, blood draw</td>
<td>All</td>
<td>Optional</td>
<td>Selection</td>
<td>Blood Draw, Blood Draw, Saliva Kit, Needle Biopsy, Cheek Swab</td>
</tr>
<tr>
<td><strong>Family Relationship</strong></td>
<td>Proband, Mother, Father, Sister, Brother (consult spreadsheet, Family Codes for more)</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>Proband, Proband, Proband, Proband, Proband</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td>Female, Male, Other (please specify)</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>Female, Female, Female, Male, Female</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td>White, American Indian or Alaska Native, Black or African American, Asian, Native Hawaiian or Other Pacific Islander, Other</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>White, American Indian or Alaska Native, White, Not allowed to collect</td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td>Hispanic or Latino, Not Hispanic or Latino</td>
<td>All</td>
<td>Required</td>
<td>Selection</td>
<td>Hispanic or Latino, Not Hispanic or Latino, Not allowed to collect</td>
</tr>
<tr>
<td><strong>Enrollment Age Days</strong></td>
<td>Number of days from birth to study enrollment</td>
<td>All</td>
<td>Required</td>
<td>Free text</td>
<td>Not Reported, 10220, 1825, 4380</td>
</tr>
<tr>
<td><strong>Phenotypes Text</strong></td>
<td>Free text, phenotypes known to exist for the participant in the study, separated by semicolons. In parental rows, can include parental phenotypes</td>
<td>All</td>
<td>Required</td>
<td>Free text</td>
<td>Crouzon, Auricular Pt; Club Foot, Congenital Diaphragmatic Hernia; Tetralogy of Fallot</td>
</tr>
<tr>
<td><strong>Phenotypes HPO</strong></td>
<td>HPO terms separated by commas or semicolons of the known phenotypes for the participant in the study</td>
<td>All</td>
<td>Encouraged</td>
<td>Ontology, free text</td>
<td>HP-0030025, HP-0001762, HP-0001363, HP-0001635, HP-0000776, HP-0004322</td>
</tr>
</tbody>
</table>

**Notes:**
- Do not use this sheet to submit data to the KF DRC (a separate template will be provided at a later point in time).
- See second tab for standard terminology to use if fields are missing, unknown, etc.
Other Attachments: Pedigree or Table

Describe Family structures (proband-parent dyads, proband-parent-sibling quads, multiplex families, consanguineous families)

- How many samples per family? How many are affected/unaffected?

<table>
<thead>
<tr>
<th>Family type</th>
<th>Number of families</th>
<th>Total Germline Samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proband/Child + Parents (unaffected) Trios</td>
<td>XX</td>
<td>XX affected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XX unaffected</td>
</tr>
<tr>
<td>Proband + 1 affected FDR + [Unaffected FDRs]</td>
<td>XX</td>
<td>XX affected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XX unaffected</td>
</tr>
<tr>
<td>Proband + 2 affected FDR + [Unaffected FDRs]</td>
<td>XX</td>
<td>XX affected</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XX unaffected</td>
</tr>
<tr>
<td>Total</td>
<td>XXX</td>
<td>XXX</td>
</tr>
</tbody>
</table>

FDR= First Degree Relative
2021 X01 Timeline

- **Oct** – Published X01 FOA
- **Dec 9** – Webinar for X01 applicants
- **Jan 19** – X01 Letters of Intent Due
- **Feb 19** – X01 Applications Due
- **April/May** – NHGRI-SEP Review X01 applications
- **June/July** – KF WG Discusses Review & Drafts Cohort Selection
- **July/Aug** – Finalize X01 cohort decision & notify recipients
- **Aug/Sept** – X01 cohorts enter pipeline
FOAs for Data Analyses

- NCI: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (Contact: rotunnom@mail.nih.gov)
FOAs for Variant Validation

• ORIP: Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)

• ORIP: Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)

• NIDCR: Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed).

• NIDCR: Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed).

• NHGRI: Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)

• To pursue collaborations with the Knockout Mouse Phenotyping Program (KOMP2), contact: KidsFirstKOMP@nih.gov
• Use the Q&A bar (lower right of your screen) to send your questions to “All Panelists”. We will read your questions out loud and answer them.

• You can ask also use the “chat” service to send private messages to the host or presenters.
Thank You!

Email Additional Questions and Comments to the Kids First Mailbox: kidsfirst@od.nih.gov